The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin
Status:
Withdrawn
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the effect of adding a SGLT-2 inhibitor (namely
Canagliflozin) on the dose of U-500 insulin required to achieve glycemic control in patients
with type 2 diabetes. We hypothesize that adding Canagliflozin to patients treated with U-500
insulin may result in significant reduction in insulin dose due to improved insulin
sensitivity and weight loss.